This Corporate Responsibility Summary Report details the social, economic, and environmental activities of AstraZeneca US. Most of the content addresses our activities in the United States, although portions of this report summarize the approach of AstraZeneca to corporate responsibility at the global level.
For additional information about AstraZeneca’s global corporate responsibility efforts, see our Global Corporate Responsibility Summary Report at www.astrazeneca.com/responsibility.
Reporting time frame
All reported data are for the 2006 calendar year, unless otherwise noted. Although we do not have a specific timetable for future reporting, we do update information and metrics on our corporate responsibility web site throughout the year.
Global reporting initiative
We used the principles set forth in both the Global Reporting Initiative (GRI) Guidelines and the AA1000 Assurance Standard as a guide while preparing this report.
Policy considerations
The pharmaceutical industry in the United States is highly regulated, and, therefore, public policy at the federal, state, and local levels often influences the decisions we make. Key issues addressed throughout this report, particularly in the Corporate Governance and Compliance, Sales and Marketing, Access to Medicines, Patient Safety, and Clinical Trials sections, reflect our policy priorities.
We regularly identify and explore key issues and engage the public, legislators, and policy makers on important health policy initiatives for the benefit of the people who use our medications. In addition to our own advocacy efforts, we work closely with the Biotechnology Industry Organization (BIO) and with our industry trade association, the Pharmaceutical Research and Manufacturers of America (PhRMA), which lobbies and communicates on behalf of the industry and its members, including AstraZeneca.
